Supplemental mevalonate increased the proliferation of cancer cells by upregulating cyclin-dependent kinase 2 (CDK2) activity and accelerating entry of cells into the S phase of cell division cycle (Duncan et al., 2004a). Here, CDK2 is linked to cancer.